Category: Mushrooms
-
![First Glance with Jody Vance: Pure Extracts (PULL.C)]()
First Glance with Jody Vance: Pure Extracts (PULL.C)
In episode 69, Jody chats with Pure Extracts (PULL.C) CEO Ben Nikolaevsky to get an insight into the companies latest updates and plans. Pure Extracts operates as a cannabis and hemp extraction company in British Columbia. It is involved in the production of cannabis, cannabidiol (CBD) oil, hemp, and functional mushrooms extracts.
-
Psychedelic Weekly Roundup with MNMD.Q, MSET.C, MYND.C, MEDI.NE, AWKN.NE, SILO, MCUR.C, NOVA.C, TRYP.C, TPIA, NEON.C
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine (MNMD.Q, MMED.NE) MindMed announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate to…
-
![Psyched for this weeks news from CYBN.NE, PSYC.C, MNMD.Q, MSET.C, FTRP.Q, MYCO.NE, RVV.C, FH.NE, CMND.C, ATAI.Q]()
Psyched for this weeks news from CYBN.NE, PSYC.C, MNMD.Q, MSET.C, FTRP.Q, MYCO.NE, RVV.C, FH.NE, CMND.C, ATAI.Q
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been a busy week for Cybin. Last week, after market close, they released their financials for the quarter ending on June 30, 2021, which showed they had…
-
![Filament Health (FH.NE) releases financials for Q2 of 2021, Tom Kineshanko transitioning from President to Founding Advisor]()
Filament Health (FH.NE) releases financials for Q2 of 2021, Tom Kineshanko transitioning from President to Founding Advisor
Filament Health (FH.NE) to release their unaudited financial results for the second quarter of 2021, a period that ended June 30, 2021. As of June 30, Filament had $7.8 million in cash and cash equivalents. This includes $5 million which was raised through a private placement that closed on June 21. That private placement included…
-
Filament Health (FH.NE) takes a natural approach to the $16 billion USD anxiety & depression market
Filament Health (FH.NE) is developing a pipeline of natural psychedelics products to treat mental health problems like depression and anxiety. August 3, 2021, FH received a patent for the technology used to transform psychedelic raw materials, like psilocybin-bearing mushroom, into pharma-grade extracts. “This approval represents important progress in the development of our IP,” stated Benjamin…
-
![Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?]()
Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?
In this episode, we take a look at a company that’s on a mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible. Filament Health (FH.NEO) is an exclusively natural psychedelic drug development company and received the first-ever psilocybin extraction and standardization patent for a public company…
-
![Filament Health (FH.NE): the natural psychedelic company flying under the radar]()
Filament Health (FH.NE): the natural psychedelic company flying under the radar
For the vast majority of the history of human use of psychedelics, they have been seen as something sacred, a gift from God or mother nature herself. Ayahuasca, which contains DMT, was given out by shamans in the Amazon as a tea. It was a spiritual experience that would purge you of your negative energy…
-
![Cybin (CYBN.N) finishes its first trading day on the NYSE]()
Cybin (CYBN.N) finishes its first trading day on the NYSE
The NYSE Cybin (CYBN.N) just finished its first trading day on the New York Stock Exchange (NYSE) after announcing the upcoming uplisting last month. It was a less than desirable day for the stock, but it’s really only a blip when factoring in the runup to the NYSE debut. In recent months we have seen…
-
![Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering]()
Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under…
-
![Revive Therapeutics (RVV.C) incredible patent-portfolio explained]()
Revive Therapeutics (RVV.C) incredible patent-portfolio explained
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…
